Home » Stocks » Penumbra

Penumbra, Inc. (PEN)

Stock Price: $232.75 USD -3.32 (-1.41%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 8.37B
Revenue (ttm) 527.20M
Net Income (ttm) 10.64M
Shares Out 35.07M
EPS (ttm) 0.30
PE Ratio 775.83
Forward PE 10,000.00
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $232.75
Previous Close $236.07
Change ($) -3.32
Change (%) -1.41%
Day's Open 224.22
Day's Range 224.22 - 233.18
Day's Volume 196,410
52-Week Range 121.80 - 237.23

More Stats

Market Cap 8.37B
Enterprise Value 8.16B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 35.07M
Float 33.00M
EPS (basic) 0.3
EPS (diluted) 0.30
FCF / Share -0.95
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.13%
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.78M
Short Ratio 11.68
Short % of Float 9.84%
Beta 0.63
PE Ratio 775.83
Forward PE 10,000.00
P/FCF Ratio n/a
PS Ratio 15.87
PB Ratio 16.25
Revenue 527.20M
Operating Income 6.52M
Net Income 10.64M
Free Cash Flow -33.54M
Net Cash 200.71M
Net Cash / Share 5.58
Gross Margin 70.55%
Operating Margin 1.24%
Profit Margin 2.00%
FCF Margin -6.36%
ROA 0.59%
ROE 1.54%
ROIC 1.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$252.80*
(8.61% upside)
Low
245
Current: $232.75
High
264
Target: 252.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue54744533426318612688.85
Revenue Growth23.03%33.31%26.75%41.5%48.27%41.26%-
Gross Profit37229321717112482.8457.88
Operating Income47.51-0.851.17-1.354.183.01-1.13
Net Income48.466.604.6614.812.37-0.830.89
Shares Outstanding34.7534.1432.9830.4611.994.614.30
Earnings Per Share1.340.180.130.440.08-0.180.14
EPS Growth644.44%38.46%-70.45%450%---
Operating Cash Flow26.6528.8112.69-12.81-20.69-6.39-3.40
Capital Expenditures-22.11-9.60-12.53-13.64-5.47-3.89-0.80
Free Cash Flow4.5419.210.16-26.44-26.16-10.28-4.19
Cash & Equivalents18920121512914951.5413.68
Total Debt82.30-----6.00
Net Cash / Debt10720121512914951.547.68
Assets66651547730826412171.15
Liabilities18092.5976.2641.7131.3322.2822.99
Book Value486422400267233-12.37-8.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Penumbra, Inc.
Country United States
Employees 2,700
CEO Adam Elsesser

Stock Information

Ticker Symbol PEN
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Devices
Unique Identifier NYSE: PEN
IPO Date September 18, 2015

Description

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; rehabilitation tools that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.